Sun Pharma Advanced Research Company Limited Approves Audited Financial Results for FY 2025-26
Sun Pharma Advanced Research Company Limited (SPARC) announced the approval of its audited Standalone and Consolidated Financial Results for the quarter and the full year ended March 31, 2026, at its Board of Directors meeting held on May 18, 2026. The company also presented the independently audited statements for the financial year and the quarter.The financial results include the audited statements for the period and are available in both standalone and consolidated formats, reflecting the performance across the group. The company reported that its only reportable business segment is 'Pharmaceutical Research and Development'.
Financial Performance Highlights
The audited financial results for the quarter and year ended March 31, 2026, show key figures in Lakhs.Standalone Financial Results (Quarter and Year Ended March 31, 2026)
| Particulars | Quarter ended 31.03.2026 (Audited) | Quarter ended 31.12.2025 (Unaudited) | Quarter ended 31.03.2025 (Audited) | Year ended 31.03.2026 (Audited) | Year ended 31.03.2025 (Audited) |
|---|---|---|---|---|---|
| Revenue from contracts with customers | 1,320 | 845 | 2,719 | 3,915 | 7,177 |
| Total revenue from operations | 1,85,322 | 845 | 2,719 | 1,87,917 | 7,177 |
| Total income | 1,85,502 | 845 | 2,719 | 1,89,000 | 7,356 |
| Total expenses | 9,432 | 7,666 | 8,817 | 32,551 | 41,878 |
| Profit / (loss) for the period | 1,76,070 | (8,057) | (6,098) | 1,55,213 | (34,522) |
| Total comprehensive profit / (loss) for the period | 1,76,177 | (7,944) | (6,137) | 1,55,420 | (34,547) |
| Basic and diluted earning / (loss) per equity share | 54.26 Not annualised | (2.48) Not annualised | (1.88) Not annualised | 47.83 Annualised | (10.64) Annualised |
Consolidated Financial Results (Quarter and Year Ended March 31, 2026)
The Group reported total income of 1,89,012 Lakhs for the year ended March 31, 2026, compared to 7,356 Lakhs in the previous year. Total expenses for the full year stood at 41,634 Lakhs.| Particulars | Quarter ended 31.03.2026 (Audited) | Quarter ended 31.12.2025 (Unaudited) | Quarter ended 31.03.2025 (Audited) | Year ended 31.03.2026 (Audited) | Year ended 31.03.2025 (Audited) |
|---|---|---|---|---|---|
| Total revenue from operations | 1,85,322 | 845 | 2,719 | 1,87,917 | 7,177 |
| Total income | 1,85,502 | 845 | 2,719 | 1,89,012 | 7,356 |
| Total expenses | 9,406 | 7,644 | 8,786 | 32,475 | 41,634 |
| Profit / (loss) for the period | 1,76,134 | (8,042) | (5,977) | 1,55,320 | (34,251) |
| Total comprehensive profit / (loss) for the period | 1,76,269 | (7,923) | (6,016) | 1,55,577 | (34,270) |
| Basic and diluted earning / (loss) per equity share | 54.27 | (2.48) | (1.84) | 47.86 | (10.55) |
Balance Sheet Summary
The consolidated balance sheet as of March 31, 2026, reported total non-current assets of 30,844 Lakhs, an increase from 30,934 Lakhs in the previous year. Total current assets reached 1,86,242 Lakhs. The total equity stood at 1,33,882 Lakhs.| Particulars | As at 31.03.2026 (Audited) | As at 31.03.2025 (Audited) |
|---|---|---|
| Total non-current assets | 30,844 | 30,934 |
| Total current assets | 1,86,242 | 2,619 |
| Total equity | 1,33,882 | (21,695) |
| Total liabilities | 83,204 | 33,553 |
| Total equity and liabilities | 2,17,086 | 55,248 |
Cash Flow Analysis
The audited consolidated statement of cash flow for the year ended March 31, 2026, showed a net cash flow used in operating activities of (23,877) Lakhs, compared to (36,029) Lakhs in the previous year. The net cash flow generated from financing activities totaled 26,139 Lakhs, resulting in an overall increase in cash and cash equivalents of 116 Lakhs at the end of the year.The key figures for cash flow activity are presented below:
| Particulars | Year ended 31.03.2026 (Audited) | Year ended 31.03.2025 (Audited) |
|---|---|---|
| Net cash flow used in operating activities (A) | (23,877) | (36,029) |
| Net cash flow (used in)/generated from investing activities (B) | (2,350) | 15,766 |
| Net cash flow generated from financing activities (C) | 26,139 | 19,925 |
| Cash and cash equivalents at the end of the year | 116 | 196 |
(All figures in Lakhs)
SPARC Stock Price Movement
Shares of Sun Pharma Advanced Research Company Limited today slipped by 1.17% to settle at ₹162.23. The stock traded on a volume of 1.33 million shares, closing closer to its day's low of ₹158.21.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: